{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:20:56Z","timestamp":1782231656439,"version":"3.54.5"},"reference-count":202,"publisher":"National Institute for Health and Care Research","issue":"51","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["12\/71\/01"],"award-info":[{"award-number":["12\/71\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\"><jats:title>Background<\/jats:title><jats:p>Diabetic retinopathy is an important cause of visual loss. Laser photocoagulation preserves vision in diabetic retinopathy but is currently used at the stage of proliferative diabetic retinopathy (PDR).<\/jats:p><\/jats:sec><jats:sec id=\"abs1-2\"><jats:title>Objectives<\/jats:title><jats:p>The primary aim was to assess the clinical effectiveness and cost-effectiveness of pan-retinal photocoagulation (PRP) given at the non-proliferative stage of diabetic retinopathy (NPDR) compared with waiting until the high-risk PDR (HR-PDR) stage was reached. There have been recent advances in laser photocoagulation techniques, and in the use of laser treatments combined with anti-vascular endothelial growth factor (VEGF) drugs or injected steroids. Our secondary questions were: (1) If PRP were to be used in NPDR, which form of laser treatment should be used? and (2) Is adjuvant therapy with intravitreal drugs clinically effective and cost-effective in PRP?<\/jats:p><\/jats:sec><jats:sec id=\"abs1-3\"><jats:title>Eligibility criteria<\/jats:title><jats:p>Randomised controlled trials (RCTs) for efficacy but other designs also used.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-4\"><jats:title>Data sources<\/jats:title><jats:p>MEDLINE and EMBASE to February 2014, Web of Science.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-5\"><jats:title>Review methods<\/jats:title><jats:p>Systematic review and economic modelling.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-6\"><jats:title>Results<\/jats:title><jats:p>The Early Treatment Diabetic Retinopathy Study (ETDRS), published in 1991, was the only trial designed to determine the best time to initiate PRP. It randomised one eye of 3711 patients with mild-to-severe NPDR or early PDR to early photocoagulation, and the other to deferral of PRP until HR-PDR developed. The risk of severe visual loss after 5 years for eyes assigned to PRP for NPDR or early PDR compared with deferral of PRP was reduced by 23% (relative risk 0.77, 99% confidence interval 0.56 to 1.06). However, the ETDRS did not provide results separately for NPDR and early PDR. In economic modelling, the base case found that early PRP could be more effective and less costly than deferred PRP. Sensitivity analyses gave similar results, with early PRP continuing to dominate or having low incremental cost-effectiveness ratio. However, there are substantial uncertainties. For our secondary aims we found 12 trials of lasers in DR, with 982 patients in total, ranging from 40 to 150. Most were in PDR but five included some patients with severe NPDR. Three compared multi-spot pattern lasers against argon laser. RCTs comparing laser applied in a lighter manner (less-intensive burns) with conventional methods (more intense burns) reported little difference in efficacy but fewer adverse effects. One RCT suggested that selective laser treatment targeting only ischaemic areas was effective. Observational studies showed that the most important adverse effect of PRP was macular oedema (MO), which can cause visual impairment, usually temporary. Ten trials of laser and anti-VEGF or steroid drug combinations were consistent in reporting a reduction in risk of PRP-induced MO.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-7\"><jats:title>Limitation<\/jats:title><jats:p>The current evidence is insufficient to recommend PRP for severe NPDR.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-8\"><jats:title>Conclusions<\/jats:title><jats:p>There is, as yet, no convincing evidence that modern laser systems are more effective than the argon laser used in ETDRS, but they appear to have fewer adverse effects. We recommend a trial of PRP for severe NPDR and early PDR compared with deferring PRP till the HR-PDR stage. The trial would use modern laser technologies, and investigate the value adjuvant prophylactic anti-VEGF or steroid drugs.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-9\"><jats:title>Study registration<\/jats:title><jats:p>This study is registered as PROSPERO CRD42013005408.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-10\"><jats:title>Funding<\/jats:title><jats:p>The National Institute for Health Research Health Technology Assessment programme.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta19510","type":"journal-article","created":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T09:34:59Z","timestamp":1437039299000},"page":"1-248","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":73,"title":["Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation"],"prefix":"10.3310","volume":"19","author":[{"given":"Pamela","family":"Royle","sequence":"first","affiliation":[{"name":"Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Mistry","sequence":"additional","affiliation":[{"name":"Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Auguste","sequence":"additional","affiliation":[{"name":"Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepson","family":"Shyangdan","sequence":"additional","affiliation":[{"name":"Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Freeman","sequence":"additional","affiliation":[{"name":"Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Lois","sequence":"additional","affiliation":[{"name":"Queens University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Waugh","sequence":"additional","affiliation":[{"name":"Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2015,7]]},"reference":[{"key":"key20150715092047195_ref1-bib1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1464-5491.2009.02718.x","article-title":"Long-term impact of retinal screening on significant diabetes-related visual impairment in the working age population","volume":"26","author":"Arun","year":"2009","journal-title":"Diabet Med"},{"key":"key20150715092047195_ref1-bib2","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.2337\/dc09-0615","article-title":"Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis","volume":"32","author":"Wong","year":"2009","journal-title":"Diabetes Care"},{"key":"key20150715092047195_ref1-bib3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2337\/dc12-0863","article-title":"Assessing progress in retinopathy outcomes in type 1 diabetes: comparing findings from the Wisconsin Diabetes Registry Study and the Wisconsin Epidemiologic Study of Diabetic Retinopathy","volume":"36","author":"LeCaire","year":"2013","journal-title":"Diabetes Care"},{"key":"key20150715092047195_ref1-bib4","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1046\/j.1464-5491.2003.01035.x","article-title":"Incidence of sight-threatening retinopathy in Type 1 diabetes in a systematic screening programme","volume":"20","author":"Younis","year":"2003","journal-title":"Diabet Med"},{"key":"key20150715092047195_ref1-bib5","unstructured":"The Royal College of Ophthalmologists. Guidelines for Diabetic Retinopathy. 2012. URL: www.rcophth.ac.uk\/page.asp?section=451&sectionTitle=Clinical+Guidelines (accessed 24 September 2013)."},{"key":"key20150715092047195_ref1-bib6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0161-6420(13)38014-2","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12","volume":"98","author":"","year":"1991","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib7","unstructured":"NHS Screening Programmes. NHS Diabetic Eye Screening Programme; 2013. URL: http:\/\/diabeticeye.screening.nhs.uk\/ (accessed 17 March 2014)."},{"key":"key20150715092047195_ref1-bib8","unstructured":"NHS Scotland. Scottish Diabetic Retinopathy Screening Collaborative 2013. URL: www.ndrs.scot.nhs.uk\/ (accessed 17 March 2014)."},{"key":"key20150715092047195_ref1-bib9","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","article-title":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9","volume":"98","author":"","year":"1991","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib10","first-page":"583","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8","volume":"88","author":"","year":"1981","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1034\/j.1600-0420.2003.00050.x","article-title":"Type 1 diabetes patients with severe non-proliferative retinopathy may benefit from panretinal photocoagulation","volume":"81","author":"Lovestam-Adrian","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"key20150715092047195_ref1-bib12","first-page":"1","article-title":"Photocoagulation in diabetic retinopathy. A multicentre study in Sweden","volume":"162","author":"Stenkula","year":"1984","journal-title":"Acta Ophthalmol Scand Suppl"},{"key":"key20150715092047195_ref1-bib13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000098254","article-title":"Laser treatment in diabetic retinopathy","volume":"221","author":"Neubauer","year":"2007","journal-title":"Ophthalmologica"},{"key":"key20150715092047195_ref1-bib14","unstructured":"Clarkson D. Multi-spot Laser Photocoagulation; 2012. URL: www.opticianonline.net\/assets\/getAsset.aspx?ItemID=6214 (accessed 23 March 2014)."},{"key":"key20150715092047195_ref1-bib15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1586\/erd.12.1","article-title":"Subthreshold diode laser micropulse photocoagulation for the treatment of diabetic macular edema","volume":"9","author":"Sivaprasad","year":"2012","journal-title":"Expert Rev Med Devices"},{"key":"key20150715092047195_ref1-bib16","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.survophthal.2010.02.005","article-title":"Micropulsed diode laser therapy: evolution and clinical applications","volume":"55","author":"Sivaprasad","year":"2010","journal-title":"Surv Ophthalmol"},{"key":"key20150715092047195_ref1-bib17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s10384-011-0095-2","article-title":"Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy","volume":"56","author":"","year":"2012","journal-title":"Jpn J Ophthalmol"},{"key":"key20150715092047195_ref1-bib18","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). Management of Diabetes: SIGN 116; 2010. URL: www.sign.ac.uk\/pdf\/sign116.pdf (accessed 24 September 2013)."},{"key":"key20150715092047195_ref1-bib19","unstructured":"National Institute for Health and Clinical Excellence (NICE). CG15 Type 1 Diabetes in Children, Young People and Adults. NICE Guideline 2012. URL: www.nice.org.uk\/guidance\/CG15\/NICEGuidance (accessed 17 March 2014)."},{"key":"key20150715092047195_ref1-bib20","unstructured":"National Institute for Health and Clinical Excellence (NICE). CG66 Type 2 Diabetes (partially updated by CG87) 2008. URL: http:\/\/guidance.nice.org.uk\/CG66 (accessed 17 March 2014)."},{"key":"key20150715092047195_ref1-bib21","author":"","year":"2011","journal-title":"Protocol: Prompt Panretinal Photocoagulation versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy"},{"key":"key20150715092047195_ref1-bib22","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"key20150715092047195_ref1-bib23","doi-asserted-by":"publisher","first-page":"e002269","DOI":"10.1136\/bmjopen-2012-002269","article-title":"Current treatments in diabetic macular oedema: systematic review and meta-analysis","volume":"3","author":"Ford","year":"2013","journal-title":"BMJ Open"},{"key":"key20150715092047195_ref1-bib24","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"","year":"2012","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib25","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"key20150715092047195_ref1-bib26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"","year":"2010","journal-title":"N Engl J Med"},{"key":"key20150715092047195_ref1-bib27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"key20150715092047195_ref1-bib28","unstructured":"Chen Y, Lu B, Zhang Q, Ma J. Therapeutic effect of fenofibrate eyedrops on diabetic retinopathy: poster 453\/D1130; ARVO Meeting, Fort Lauderdale, FL, USA, 6 May 2012."},{"key":"key20150715092047195_ref1-bib29","unstructured":"McCall B. World First Approval for Fenofibrate in Diabetic Retinopathy; 2013. URL: www.medscape.com\/viewarticle\/815213 (accessed 17 March 2014)."},{"key":"key20150715092047195_ref1-bib30","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jcjo.2011.12.025","article-title":"Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy","volume":"47","author":"Hooper","year":"2012","journal-title":"Can J Ophthalmol"},{"key":"key20150715092047195_ref1-bib31","unstructured":"American Academy of Ophthalmology. Diabetic Retinopathy PPP\u2013updated October 2012; 2008. URL: http:\/\/one.aao.org\/preferred-practice-pattern\/diabetic-retinopathy-ppp--september-2008\u20134th-print (accessed 29 September 2013)."},{"key":"key20150715092047195_ref1-bib32","unstructured":"Australian Government: National Health and Medical Research Council (NHMRC), Mitchell P, Foran S. Guidelines for the Management of Diabetic Retinopathy; 2008. URL: www.nhmrc.gov.au\/_files_nhmrc\/publications\/attachments\/di15.pdf (accessed 17 March 2014)."},{"key":"key20150715092047195_ref1-bib33","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1001\/jama.298.8.902","article-title":"Management of diabetic retinopathy: a systematic review","volume":"298","author":"Mohamed","year":"2007","journal-title":"JAMA"},{"key":"key20150715092047195_ref1-bib34","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clin Res Ed)"},{"key":"key20150715092047195_ref1-bib35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0002-9394(76)90292-0","article-title":"Preliminary report on effects of photocoagulation therapy","volume":"81","author":"","year":"1976","journal-title":"Am J Ophthalmol"},{"key":"key20150715092047195_ref1-bib36","first-page":"149","article-title":"Diabetic retinopathy study, report number 6: design, methods, and baseline results","volume":"21","author":"","year":"1981","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20150715092047195_ref1-bib37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0161-6420(78)35693-1","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings","volume":"85","author":"","year":"1978","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00004397-198702740-00004","article-title":"Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14","volume":"27","author":"","year":"1987","journal-title":"Int Ophthalmol Clin"},{"key":"key20150715092047195_ref1-bib39","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0161-6420(87)33526-2","article-title":"Macular edema in Diabetic Retinopathy Study patients; Diabetic Retinopathy Study Report Number 12","volume":"94","author":"Ferris","year":"1987","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib40","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0161-6420(13)38009-9","article-title":"Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics; ETDRS report number 7","volume":"98","author":"","year":"1991","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0002-9394(98)00309-2","article-title":"Causes of severe visual loss in the early treatment diabetic retinopathy study; ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group","volume":"127","author":"Fong","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"key20150715092047195_ref1-bib42","first-page":"505","article-title":"Early photocoagulation in patients with either type I or type II diabetes","volume":"94","author":"Ferris","year":"1996","journal-title":"Trans Am Ophthalmol Soc"},{"key":"key20150715092047195_ref1-bib43","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1001\/archopht.1985.01050110038020","article-title":"Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial; Diabetic Retinopathy Vitrectomy Study Report 2","volume":"103","author":"","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"key20150715092047195_ref1-bib44","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0161-6420(92)31779-8","article-title":"Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group","volume":"99","author":"Flynn","year":"1992","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib45","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/archopht.117.12.1600","article-title":"Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25","volume":"117","author":"Chew","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"key20150715092047195_ref1-bib46","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/bmj.315.7116.1105","article-title":"Why some cases of retinopathy worsen when diabetic control improves","volume":"315","author":"Chantelau","year":"1997","journal-title":"BMJ (Clin Res Ed)"},{"key":"key20150715092047195_ref1-bib47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-0-387-85900-2_9","volume-title":"Diabetic Retinopathy: Evidence Based Management","author":"Pautler","year":"2010"},{"key":"key20150715092047195_ref1-bib48","first-page":"265","volume-title":"Vision in Vehicles III","author":"Williamson"},{"key":"key20150715092047195_ref1-bib49","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2005.02.029","article-title":"Visual dysfunction after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision","volume":"140","author":"Shimura","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"key20150715092047195_ref1-bib50","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ajo.2005.03.025","article-title":"Visual dysfunction after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision","volume":"140","author":"Browning","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"key20150715092047195_ref1-bib51","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.ophtha.2003.06.028","article-title":"Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography","volume":"111","author":"Browning","year":"2004","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib52","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1600-0420.2006.00694.x","article-title":"Optical coherence tomography: a key to the future management of patients with diabetic macular oedema","volume":"84","author":"Massin","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"key20150715092047195_ref1-bib53","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ophtha.2007.06.042","article-title":"The relationship of macular thickness to clinically graded diabetic retinopathy severity in eyes without clinically detected diabetic macular edema","volume":"115","author":"Browning","year":"2008","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib54","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/archopht.125.4.469","article-title":"Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema","volume":"125","author":"","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"key20150715092047195_ref1-bib55","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s12009-000-0027-0","article-title":"Diode laser scatter photocoagulation in diabetic retinopathy","volume":"32","author":"Tewari","year":"2000","journal-title":"Ann Ophthalmol"},{"key":"key20150715092047195_ref1-bib56","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1136\/bjo.2004.051060","article-title":"\u2018Light\u2019 versus \u2018classic\u2019 laser treatment for clinically significant diabetic macular oedema","volume":"89","author":"Bandello","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"key20150715092047195_ref1-bib57","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jamaophthalmol.2013.4154","article-title":"Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial","volume":"131","author":"Bressler","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"key20150715092047195_ref1-bib58","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/milmed\/168.7.553","article-title":"A comparative study of panretinal photocoagulation and vitrectomy for advanced diabetic retinopathy","volume":"168","author":"Brown","year":"2003","journal-title":"Mil Med"},{"key":"key20150715092047195_ref1-bib59","unstructured":"Cardillo JA, Lavinsky D, Melo LAS, Dare A, Castro L, Costa RA, et al. Comparison of the modified early treatment diabetic retinopathy study and normal or high density subthreshold infrared micro pulsed photocoagulation for diabetic macular edema; 2008. URL: www.iovs.org: ARVO e-abstract no. 1566."},{"key":"key20150715092047195_ref1-bib60","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ajo.2011.05.035","article-title":"Panretinal photocoagulation for proliferative diabetic retinopathy: pattern scan laser versus argon laser","volume":"153","author":"Chappelow","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"key20150715092047195_ref1-bib61","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/IAE.0b013e31819a5fc2","article-title":"Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy","volume":"29","author":"Cho","year":"2009","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib62","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1001\/archophthalmol.2008.565","article-title":"Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings","volume":"127","author":"","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"key20150715092047195_ref1-bib63","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3928\/1542-8877-20040301-03","article-title":"Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy","volume":"35","author":"Gurelik","year":"2004","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"key20150715092047195_ref1-bib64","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3928\/1542-8877-20000701-07","article-title":"Combined modified grid and panretinal photocoagulation for diffuse diabetic macular edema and proliferative diabetic retinopathy","volume":"31","author":"Lee","year":"2000","journal-title":"Ophthalmic Surg Las"},{"key":"key20150715092047195_ref1-bib65","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/IAE.0b013e3181c701e0","article-title":"Changes in macular thickness after panretinal photocoagulation in patients with severe diabetic retinopathy and no macular edema","volume":"30","author":"Lee","year":"2010","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib66","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/sj.eye.6702725","article-title":"Subthreshold diode micropulse panretinal photocoagulation for proliferative diabetic retinopathy","volume":"22","author":"Luttrull","year":"2008","journal-title":"Eye"},{"key":"key20150715092047195_ref1-bib67","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1097\/IAE.0b013e31818356fb","article-title":"Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy","volume":"28","author":"Mason","year":"2008","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib68","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1755-3768.2011.02307.x","article-title":"Optos-guided pattern scan laser (PASCAL)-targeted retinal photocoagulation in proliferative diabetic retinopathy","volume":"91","author":"Muqit","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"key20150715092047195_ref1-bib69","first-page":"36","article-title":"Scatter photocoagulation: pros and cons with old and new laser equipments","volume":"90","author":"Summanen","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"key20150715092047195_ref1-bib70","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1089\/pho.2010.2830","article-title":"Subthreshold micropulse diode laser and double frequency neodymium: YAG laser in treatment of diabetic macular edema: a prospective, randomized study using multifocal electroretinography","volume":"29","author":"Venkatesh","year":"2011","journal-title":"Photomed Laser Surg"},{"key":"key20150715092047195_ref1-bib71","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1097\/IAE.0b013e3181c96986","article-title":"Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation","volume":"30","author":"Vujosevic","year":"2010","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib72","first-page":"194","article-title":"Efficacy and safety of PASCAL photocoagulator in the treatment of proliferative diabetic retinopathy","volume":"50","author":"Zucchiatti","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20150715092047195_ref1-bib73","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1076\/soph.16.1.12.4223","article-title":"Light panretinal photocoagulation (LPRP) versus classic panretinal photocoagulation (CPRP) in proliferative diabetic retinopathy","volume":"16","author":"Bandello","year":"2001","journal-title":"Semin Ophthalmol"},{"key":"key20150715092047195_ref1-bib74","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1136\/bjo.2009.176677","article-title":"Pain responses of Pascal 20 ms multi-spot and 100 ms single-spot panretinal photocoagulation: Manchester Pascal Study, MAPASS report 2","volume":"94","author":"Muqit","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"key20150715092047195_ref1-bib75","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/archophthalmol.2010.60","article-title":"Single-session vs multiple-session pattern scanning laser panretinal photocoagulation in proliferative diabetic retinopathy: The Manchester Pascal Study","volume":"128","author":"Muqit","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"key20150715092047195_ref1-bib76","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/eye.2011.188","article-title":"Pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4","volume":"25","author":"Muqit","year":"2011","journal-title":"Eye"},{"key":"key20150715092047195_ref1-bib77","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2012-302189","article-title":"Pilot randomised clinical trial of Pascal TargETEd Retinal versus variable fluence PANretinal 20\u2009ms laser in diabetic retinopathy: PETER PAN study","volume":"97","author":"Muqit","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"key20150715092047195_ref1-bib78","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1097\/IAE.0b013e318203c140","article-title":"Single session of Pascal versus multiple sessions of conventional laser for panretinal photocoagulation in proliferative diabetic retinopathy: a comparative study","volume":"31","author":"Muraly","year":"2011","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib79","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/sj.eye.6703026","article-title":"Pain response and follow-up of patients undergoing panretinal laser photocoagulation with reduced exposure times","volume":"22","author":"Al-Hussainy","year":"2008","journal-title":"Eye"},{"key":"key20150715092047195_ref1-bib80","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.ophtha.2003.05.008","article-title":"Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision","volume":"110","author":"Shimura","year":"2003","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib81","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00417-012-2167-5","article-title":"Pain score of patients undergoing single spot, short pulse laser versus conventional laser for diabetic retinopathy","volume":"251","author":"Mirshahi","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key20150715092047195_ref1-bib82","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/IAE.0b013e3181c70127","article-title":"Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser","volume":"30","author":"Nagpal","year":"2010","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib83","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.sjopt.2011.01.006","article-title":"Pascal laser versus conventional laser for treatment of diabetic retinopathy","volume":"25","author":"Salman","year":"2011","journal-title":"Saudi J Ophthalmol"},{"key":"key20150715092047195_ref1-bib84","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jcrs.2008.02.019","article-title":"Management of type 2 diabetics requiring panretinal photocoagulation and cataract surgery","volume":"34","author":"Suto","year":"2008","journal-title":"J Cataract Refract Surg"},{"key":"key20150715092047195_ref1-bib85","first-page":"1635","article-title":"Clinical analysis of preproliferative diabetic retinopathy prognosis of photocoagulation","volume":"40","author":"Shimizu","year":"1989","journal-title":"Folia Ophthalmol Jpn"},{"key":"key20150715092047195_ref1-bib86","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1097\/IAE.0b013e3182695b03","article-title":"Re: Single session of Pascal versus multiple sessions of conventional laser for panretinal photocoagulation in proliferative diabetic retinopathy: a comparative study","volume":"32","author":"Jojo","year":"2012","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib87","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1097\/IAE.0b013e3182695be4","article-title":"Re: Single session of Pascal versus multiple sessions of conventional laser for panretinal photocoagulation in proliferative diabetic retinopathy: a comparative study","volume":"32","author":"Muraly","year":"2012","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib88","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/BF00921112","article-title":"Diode versus argon-green laser panretinal photocoagulation in proliferative diabetic retinopathy: a randomized study in 44 eyes with a long follow-up time","volume":"231","author":"Bandello","year":"1993","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key20150715092047195_ref1-bib89","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/bjo.2008.146712","article-title":"Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema","volume":"93","author":"Figueira","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"key20150715092047195_ref1-bib90","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1136\/bjo.2003.040949","article-title":"Subthreshold micropulse diode laser treatment in diabetic macular oedema","volume":"88","author":"Laursen","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"key20150715092047195_ref1-bib91","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1167\/iovs.10-6828","article-title":"Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema","volume":"52","author":"Lavinsky","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20150715092047195_ref1-bib92","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0895-4356(00)00305-X","article-title":"Are randomized clinical trials good for us (in the short term)? Evidence for a \u2018trial effect\u2019","volume":"54","author":"Braunholtz","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"key20150715092047195_ref1-bib93","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.mr000009.pub4","article-title":"Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate","volume":"3","author":"Vist","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"key20150715092047195_ref1-bib94","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/IAE.0b013e318042d32c","article-title":"Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review","volume":"27","author":"Fong","year":"2007","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib95","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ophtha.2006.06.052","article-title":"Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema","volume":"114","author":"","year":"2007","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib96","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1444-0938.2011.00585.x","article-title":"Retinal function and morphology of severe non-proliferative diabetic retinopathy before and after retinal photocoagulation","volume":"94","author":"Du","year":"2011","journal-title":"Clin Exp Optom"},{"key":"key20150715092047195_ref1-bib97","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/00006982-200408000-00002","article-title":"Progressive enlargement of scattered photocoagulation scars in diabetic retinopathy","volume":"24","author":"Maeshima","year":"2004","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib98","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3109\/15569527.2010.489336","article-title":"Internal ophthalmoplegia after retinal laser photocoagulation","volume":"29","author":"Raman","year":"2010","journal-title":"Cutan Ocul Toxicol"},{"key":"key20150715092047195_ref1-bib99","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00417-009-1147-x","article-title":"Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy","volume":"247","author":"Shimura","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key20150715092047195_ref1-bib100","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/OPX.0000000000000103","article-title":"Spatial changes of central field loss in diabetic retinopathy after laser","volume":"91","author":"Wang","year":"2014","journal-title":"Optom Vis Sci"},{"key":"key20150715092047195_ref1-bib101","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S0002-9394(99)00322-0","article-title":"One-year outcomes of panretinal photocoagulation in proliferative diabetic retinopathy","volume":"129","author":"Kaiser","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"key20150715092047195_ref1-bib102","doi-asserted-by":"publisher","first-page":"321","DOI":"10.5455\/medarh.2012.66.321-323","article-title":"Comparing two techniques of panretinal photocoagulation on visual acuity on patients with proliferative diabetic retinopathy","volume":"66","author":"Kovacic","year":"2012","journal-title":"Med Arh"},{"key":"key20150715092047195_ref1-bib103","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1038\/eye.2008.394","article-title":"Routine, single session, indirect laser for proliferative diabetic retinopathy","volume":"23","author":"Tinley","year":"2009","journal-title":"Eye"},{"key":"key20150715092047195_ref1-bib104","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/bjo.2009.164996","article-title":"Pattern scan laser photocoagulation: safety and complications, experience after 1301 consecutive cases","volume":"94","author":"Velez-Montoya","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"key20150715092047195_ref1-bib105","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3129\/i10-108","article-title":"Choroidal detachment after PASCAL photocoagulation","volume":"46","author":"Natesh","year":"2011","journal-title":"Can J Ophthalmol"},{"key":"key20150715092047195_ref1-bib106","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.12.2009.2511","article-title":"An unusual case of acute angle closure glaucoma following argon laser pan retinal photocoagulation","author":"Kapoor","year":"2010","journal-title":"BMJ Case Rep"},{"key":"key20150715092047195_ref1-bib107","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1038\/eye.2008.421","article-title":"Pain relief during panretinal photocoagulation for diabetic retinopathy: a national survey","volume":"23","author":"Richardson","year":"2009","journal-title":"Eye"},{"key":"key20150715092047195_ref1-bib108","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/eye.1998.14","article-title":"The National Diabetic Retinopathy Laser Treatment Audit. II. Proliferative retinopathy","volume":"12","author":"Bailey","year":"1998","journal-title":"Eye"},{"key":"key20150715092047195_ref1-bib109","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1097\/IAE.0b013e3181f57f84","article-title":"Re: Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser","volume":"30","author":"Stanga","year":"2010","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib110","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMct0908432","article-title":"Panretinal photocoagulation for proliferative diabetic retinopathy","volume":"365","author":"Bressler","year":"2011","journal-title":"N Engl J Med"},{"key":"key20150715092047195_ref1-bib111","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1034\/j.1600-0420.2001.790311.x","article-title":"Quantitative assessment of retinal thickness in diabetic patients with and without clinically significant macular edema using optical coherence tomography","volume":"79","author":"Yang","year":"2001","journal-title":"Acta Ophthalmol Scand"},{"key":"key20150715092047195_ref1-bib112","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/eye.1995.118","article-title":"How much blame can be placed on laser photocoagulation for failure to attain driving standards?","volume":"9","author":"Mackie","year":"1995","journal-title":"Eye"},{"key":"key20150715092047195_ref1-bib113","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1464-5491.2008.02623.x","article-title":"Long-term review of driving potential following bilateral panretinal photocoagulation for proliferative diabetic retinopathy","volume":"26","author":"Vernon","year":"2009","journal-title":"Diabet Med"},{"key":"key20150715092047195_ref1-bib114","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/eye.1992.96","article-title":"Passing the DLVC field regulations following bilateral pan-retinal photocoagulation in diabetics","volume":"6","author":"Hulbert","year":"1996","journal-title":"Eye"},{"key":"key20150715092047195_ref1-bib115","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/eye.1999.132","article-title":"Altering the pattern of panretinal photocoagulation: could the visual field for driving be preserved?","volume":"13","author":"Davies","year":"1999","journal-title":"Eye"},{"key":"key20150715092047195_ref1-bib116","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/eye.1999.129","article-title":"Can altering the pattern of laser photocoagulation for proliferative diabetic retinopathy help retain visual fields for driving?","volume":"13","author":"Quinn","year":"1999","journal-title":"Eye"},{"key":"key20150715092047195_ref1-bib117","unstructured":"Whittington Health NHS. Preparing for Laser Treatment for Diabetic Retinopathy and Maculopathy; 2013. URL: www.whittington.nhs.uk\/document.ashx?id\u2009=\u2009818 (accessed 25 March 2014)."},{"key":"key20150715092047195_ref1-bib118","unstructured":"Diabetes UK. Driving and Diabetes; 2009. URL: www.diabetes.org.uk\/upload\/How%20we%20help\/catalogue\/DrivingandDiabetes_Final_ToUpload.pdf (accessed 25 March 2014)."},{"key":"key20150715092047195_ref1-bib119","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1136\/bjo.2009.168997","article-title":"Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy","volume":"94","author":"Cho","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"key20150715092047195_ref1-bib120","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/IAE.0b013e318217d739","article-title":"Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal\/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation","volume":"31","author":"","year":"2011","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib121","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1111\/j.1755-3768.2011.02364.x","article-title":"Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naive proliferative and severe nonproliferative diabetic retinopathy","volume":"90","author":"Ernst","year":"2012","journal-title":"Acta Opthalmol"},{"key":"key20150715092047195_ref1-bib122","doi-asserted-by":"publisher","first-page":"e567","DOI":"10.1111\/j.1755-3768.2011.02184.x","article-title":"Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy","volume":"89","author":"Filho","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"key20150715092047195_ref1-bib123","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1590\/S0004-27492013000100006","article-title":"Panretinal photocoagulation versus intravitreal injection retreatment pain in high-risk proliferative diabetic retinopathy","volume":"76","author":"Lucena","year":"2013","journal-title":"Arq Bras Oftalmol"},{"key":"key20150715092047195_ref1-bib124","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/112067210801800215","article-title":"Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial","volume":"18","author":"Mirshahi","year":"2008","journal-title":"Eur J Ophthalmol"},{"key":"key20150715092047195_ref1-bib125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000348605","article-title":"Structural and functional assessment of macula in patients with high-risk proliferative diabetic retinopathy submitted to Panretinal photocoagulation and associated intravitreal bevacizumab injections: a comparative, randomised, controlled trial","volume":"230","author":"Preti","year":"2013","journal-title":"Ophthalmologica"},{"key":"key20150715092047195_ref1-bib126","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1600-0420.2007.01056.x","article-title":"Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study)","volume":"86","author":"Tonello","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"key20150715092047195_ref1-bib127","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ajo.2008.08.024","article-title":"Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial","volume":"147","author":"Maia","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key20150715092047195_ref1-bib128","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/IAE.0b013e3181b4f125","article-title":"Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema","volume":"30","author":"Mirshahi","year":"2010","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib129","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ophtha.2005.10.035","article-title":"Posterior sub-Tenon\u2019s capsule injection of triamcinolone acetonide prevents panretinal photocoagulation-induced visual dysfunction in patients with severe diabetic retinopathy and good vision","volume":"113","author":"Shimura","year":"2006","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib130","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/bjo.2008.152041","article-title":"Randomised controlled trial of posterior sub-Tenon triamcinolone as adjunct to panretinal photocoagulation for treatment of diabetic retinopathy","volume":"93","author":"Unoki","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"key20150715092047195_ref1-bib131","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","article-title":"Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"issue":"36","key":"key20150715092047195_ref1-bib132","doi-asserted-by":"publisher","DOI":"10.3310\/hta8360","article-title":"Review of guidelines for good practice in decision-analytic modelling in health technology assessment","volume":"8","author":"Philips","year":"2004","journal-title":"Health Technol Assess"},{"key":"key20150715092047195_ref1-bib133","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1097\/IAE.0b013e3182928b33","article-title":"Effect of pan-retinal photocoagulation treatment on vision-related quality of life of patients with proliferative diabetic retinopathy","volume":"33","author":"Fenwick","year":"2013","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib134","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1464-5491.2005.01736.x","article-title":"Reported symptoms and quality-of-life impacts in patients having laser treatment for sight-threatening diabetic retinopathy","volume":"23","author":"Scanlon","year":"2006","journal-title":"Diabet Med"},{"key":"key20150715092047195_ref1-bib135","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/IAE.0b013e31826b0c06","article-title":"Effect of panretinal photocoagulation treatment on vision-related quality of life of patients with proliferative diabetic retinopathy","volume":"33","author":"Tsilimbaris","year":"2013","journal-title":"Retina"},{"key":"key20150715092047195_ref1-bib136","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2147\/PPA.S11972","article-title":"Patient preferences in the treatment of diabetic retinopathy","volume":"5","author":"Wirostko","year":"2011","journal-title":"Patient Prefer Adherence"},{"key":"key20150715092047195_ref1-bib137","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1600-0420.2005.00455.x","article-title":"Photocoagulation for diabetic retinopathy: determinants of patient satisfaction and the patient\u2013provider relationship","volume":"83","author":"Mozaffarieh","year":"2005","journal-title":"Acta Ophthalmol Scand"},{"key":"key20150715092047195_ref1-bib138","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/j.1464-5491.2006.01957.x","article-title":"Perception of, and anxiety levels induced by, laser treatment in patients with sight-threatening diabetic retinopathy. A multicentre study","volume":"23","author":"Trento","year":"2006","journal-title":"Diabet Med"},{"key":"key20150715092047195_ref1-bib139","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"key20150715092047195_ref1-bib140","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/eye.2012.137","article-title":"Estimating quality-adjusted life years from patient-reported visual functioning","volume":"26","author":"Browne","year":"2012","journal-title":"Eye"},{"key":"key20150715092047195_ref1-bib141","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s11136-009-9499-6","article-title":"Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration","volume":"18","author":"Payakachat","year":"2009","journal-title":"Qual Life Res"},{"key":"key20150715092047195_ref1-bib142","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1136\/bmj.320.7248.1530","article-title":"Using conjoint analysis to elicit preferences for health care","volume":"320","author":"Ryan","year":"2000","journal-title":"BMJ (Clin Res Ed)"},{"key":"key20150715092047195_ref1-bib143","unstructured":"Diabetes in Scotland. Scottish Diabetes Survey; 2012. URL: www.diabetesinscotland.org.uk\/Publications.aspx?catId\u2009=\u20093 (accessed 21 March 2014)."},{"key":"key20150715092047195_ref1-bib144","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1007\/s00125-004-1431-6","article-title":"Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes: the Linkoping Diabetes Complications Study","volume":"47","author":"Nordwall","year":"2004","journal-title":"Diabetologia"},{"key":"key20150715092047195_ref1-bib145","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0161-6420(95)30973-6","article-title":"Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial","volume":"102","author":"","year":"1995","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib146","author":"","journal-title":"National Diabetes Audit 2011\u20132012 Report 1: Care Processes and Treatment Targets"},{"key":"key20150715092047195_ref1-bib147","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"","year":"2005","journal-title":"N Engl J Med"},{"key":"key20150715092047195_ref1-bib148","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/S0161-6420(98)91020-X","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes","volume":"105","author":"Klein","year":"1998","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib149","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s001250051594","article-title":"UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis","volume":"44","author":"Stratton","year":"2001","journal-title":"Diabetologia"},{"key":"key20150715092047195_ref1-bib150","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.2337\/dc12-0790","article-title":"Predicting development of proliferative diabetic retinopathy","volume":"36","author":"Harris Nwanyanwu","year":"2013","journal-title":"Diabetes Care"},{"key":"key20150715092047195_ref1-bib151","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/sj.eye.6702771","article-title":"Five-year incidence and progression of diabetic retinopathy in a defined older population: the Blue Mountains Eye Study","volume":"21","author":"Cikamatana","year":"2007","journal-title":"Eye"},{"key":"key20150715092047195_ref1-bib152","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2337\/dc11-0943","article-title":"Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England","volume":"35","author":"Jones","year":"2012","journal-title":"Diabetes Care"},{"key":"key20150715092047195_ref1-bib153","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1046\/j.1442-9071.2003.00685.x","article-title":"Five-year incidence of diabetic retinopathy in the Melbourne Visual Impairment Project","volume":"31","author":"McCarty","year":"2003","journal-title":"Clin Experiment Ophthalmol"},{"key":"key20150715092047195_ref1-bib154","first-page":"233","article-title":"Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report 18","volume":"39","author":"Davis","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20150715092047195_ref1-bib155","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.ophtha.2008.08.023","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes","volume":"115","author":"Klein","year":"2008","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib156","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1111\/aos.12074","article-title":"The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010","volume":"91","author":"Scanlon","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"key20150715092047195_ref1-bib157","unstructured":"Ting HYJ, Martin DK, Haas M. A Markov Model of Diabetic Retinopathy Progression for the Economic Evaluation of a novel DR prognostic device: CHERE Working Paper 2007\/14; 2007. URL: www.chere.uts.edu.au\/pdf\/wp2007_14.pdf (accessed 18 March 2014)."},{"issue":"60","key":"key20150715092047195_ref1-bib158","doi-asserted-by":"publisher","DOI":"10.3310\/hta13600","article-title":"Colour vision testing for diabetic retinopathy: a systematic review of diagnostic accuracy and economic evaluation","volume":"13","author":"Rodgers","year":"2009","journal-title":"Health Technol Assess"},{"key":"key20150715092047195_ref1-bib159","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1185\/030079904X2006","article-title":"Validation of the CORE diabetes model against epidemiological and clinical studies","volume":"20","author":"Palmer","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"key20150715092047195_ref1-bib160","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ophtha.2012.09.002","article-title":"The cost-utility of telemedicine to screen for diabetic retinopathy in India","volume":"120","author":"Rachapelle","year":"2013","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib161","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0002-9394(99)00146-4","article-title":"Utility values and diabetic retinopathy","volume":"128","author":"Brown","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"key20150715092047195_ref1-bib162","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S0002-9394(01)01364-2","article-title":"Vision loss among diabetics in a group model Health Maintenance Organization (HMO)","volume":"133","author":"Fong","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"key20150715092047195_ref1-bib163","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s11136-008-9399-1","article-title":"Lower visual acuity predicts worse utility values among patients with type 2 diabetes","volume":"17","author":"Smith","year":"2008","journal-title":"Qual Life Res"},{"key":"key20150715092047195_ref1-bib164","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/j.1475-6773.2011.01263.x","article-title":"The cost-effectiveness of three screening alternatives for people with diabetes with no or early diabetic retinopathy","volume":"46","author":"Rein","year":"2011","journal-title":"Health Serv Res"},{"key":"key20150715092047195_ref1-bib165","volume-title":"NHS Reference Costs 2012 to 2013","author":"","year":"2013"},{"key":"key20150715092047195_ref1-bib166","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1136\/bjophthalmol-2011-300726","article-title":"Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial","volume":"96","author":"Mitchell","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"key20150715092047195_ref1-bib167","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2165\/00019053-200624020-00008","article-title":"How much is the cost of visual impairment: caveat emptor","volume":"24","author":"Meads","year":"2006","journal-title":"PharmacoEconomics"},{"key":"key20150715092047195_ref1-bib168","volume-title":"Unit Costs of Health and Social Care 2013","author":"Curtis","year":"2013"},{"key":"key20150715092047195_ref1-bib169","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0161-6420(85)34002-2","article-title":"Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1","volume":"92","author":"","year":"1985","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib170","unstructured":"Office for National Statistics (ONS). UK Interim Life Tables, 1980\u201382 to 2008\u201310. 2011. URL: http:\/\/www.ons.gov.uk\/ons\/taxonomy\/index.html?nscl\u2009=\u2009Interim+Life+Tables (accessed 18 April 2014)."},{"key":"key20150715092047195_ref1-bib171","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-005-0120-4","article-title":"All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992\u20131999","volume":"49","author":"Soedamah-Muthu","year":"2006","journal-title":"Diabetologia"},{"key":"key20150715092047195_ref1-bib172","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1464-5491.2006.01838.x","article-title":"Mortality in people with type 2 diabetes in the UK","volume":"23","author":"Mulnier","year":"2006","journal-title":"Diabet Med"},{"key":"key20150715092047195_ref1-bib173","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2337\/diacare.28.3.617","article-title":"Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27","volume":"28","author":"Cusick","year":"2005","journal-title":"Diabetes Care"},{"key":"key20150715092047195_ref1-bib174","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1001\/archopht.117.11.1487","article-title":"Association of ocular disease and mortality in a diabetic population","volume":"117","author":"Klein","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"key20150715092047195_ref1-bib175","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"issue":"47","key":"key20150715092047195_ref1-bib176","doi-asserted-by":"publisher","DOI":"10.3310\/hta11470","article-title":"The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model","volume":"11","author":"Fox","year":"2007","journal-title":"Health Technol Assess"},{"key":"key20150715092047195_ref1-bib177","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780192631770.001.0001","volume-title":"Economic Evaluation in HealthCare: Merging Theory with Practice","author":"Drummond","year":"2001"},{"key":"key20150715092047195_ref1-bib178","volume-title":"British National Formulary","author":"","year":"2013"},{"key":"key20150715092047195_ref1-bib179","doi-asserted-by":"crossref","unstructured":"National Institute for Health and Clinical Excellence (NICE). Bevacizumab (Avastin) for Eye Conditions. Report of Findings from a Workshop Held at NICE on 13 July 2010. 2010. URL: www.nice.org.uk\/media\/AC2\/3C\/BevacizumabEyeConditionsPrescopingReport.pdf (accessed 25 March 2014).","DOI":"10.1002\/psb.1279"},{"key":"key20150715092047195_ref1-bib180","unstructured":"NICE Decision Support Unit. Macular Oedema \u2013 Bevacizumab as a Comparator; 2013. URL: www.nicedsu.org.uk\/Macular-oedema--bevacizumab(2804604).htm (accessed 25 March 2014)."},{"key":"key20150715092047195_ref1-bib181","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/j.1464-5491.2008.02430.x","article-title":"Health utility values associated with diabetic retinopathy","volume":"25","author":"Lloyd","year":"2008","journal-title":"Diabet Med"},{"key":"key20150715092047195_ref1-bib182","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/OPX.0000000000000005","article-title":"Responsiveness of the EQ-5D to the effects of low vision rehabilitation","volume":"90","author":"Malkin","year":"2013","journal-title":"Optom Vis Sci"},{"key":"key20150715092047195_ref1-bib183","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. URL: http:\/\/publications.nice.org.uk\/guide-to-the-methods-of-technology-appraisal-2013-pmg9 (accessed 21 March 2014)."},{"key":"key20150715092047195_ref1-bib184","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1080\/09286580801979417","article-title":"Vision and quality of life: development of methods for the VisQoL vision-related utility instrument","volume":"15","author":"Peacock","year":"2008","journal-title":"Ophthalmic Epidemiol"},{"key":"key20150715092047195_ref1-bib185","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1167\/iovs.04-1389","article-title":"Vision and quality of life: the development of a utility measure","volume":"46","author":"Misajon","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20150715092047195_ref1-bib186","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.ophtha.2012.01.049","article-title":"Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"119","author":"Dewan","year":"2012","journal-title":"Ophthalmology"},{"key":"key20150715092047195_ref1-bib187","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7326\/M13-0768","article-title":"Cost-effectiveness of treatment of diabetic macular edema","volume":"160","author":"Pershing","year":"2014","journal-title":"Ann Intern Med"},{"key":"key20150715092047195_ref1-bib188","first-page":"5760","article-title":"Proliferative Diabetic Retinopathy. A comparison of anti-VGEF therapy and laser in preserving visual function in patients with proliferative diabetic retinopathy","volume":"54","author":"Estudillo","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20150715092047195_ref1-bib189","first-page":"4599","article-title":"The impact on vision and regression of retinal neovascularization of anti-VEGF induction in combination with quarterly anti-VEGF maintenance or selective PRP versus standard PRP","volume":"54","author":"Gonzalez","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20150715092047195_ref1-bib190","first-page":"2439","article-title":"Combination of intravitreal injection of Pegaptanib plus progressive PRP versus full PRP alone in patients with High Risk Proliferative Diabetic Retinopathy","volume":"54","author":"Leal","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20150715092047195_ref1-bib191","unstructured":"Madeira MIA, Neves J, Abdala M. A different approach of pan retinal photocoagulation for the treatment of proliferative diabetic retinopathy (external ring photocoagulation). Paper presented at the IX Euretina Congress, Nice, May 2009."},{"key":"key20150715092047195_ref1-bib192","first-page":"2447","article-title":"Evaluation of choroidal thickness in high-risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a 3 months, randomized, controlled and masked clinical trial","volume":"54","author":"Preti","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20150715092047195_ref1-bib193","first-page":"357","article-title":"Structural and functional macular evaluation in proliferative diabetic retinopathy patients treated using panretinal photocoagulation combined with intravitreal bevacizumab injections","volume":"53","author":"Preti","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20150715092047195_ref1-bib194","first-page":"1239","article-title":"Double-masked trial demonstrates superiority of combined ranibizumab plus laser versus laser in patients with diabetic macular edema with or without proliferative diabetic retinopathy","volume":"54","author":"Lohmann","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20150715092047195_ref1-bib195","first-page":"4028","article-title":"Effects of intravitreal ranibizumab on diabetic retinopathy severity: 36 month data from the RISE and RIDE phase III trials","volume":"54","author":"Ehrlich","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20150715092047195_ref1-bib196","first-page":"366","article-title":"Exploratory analysis of diabetic retinopathy worsening (progression) at 1 year and 3 years in a randomized clinical trial evaluating ranibizumab and triamcinolone","volume":"53","author":"Miller","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20150715092047195_ref1-bib197","first-page":"5761","article-title":"Intravitreal ranibizumab combined with panretinal photocoagulation in patients with treatment-naive proliferative diabetic retinopathy","volume":"54","author":"Ferraz","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20150715092047195_ref1-bib198","unstructured":"Medical Research Council NIHR. Efficacy and Mechanism Evaluation Programming EME Board: decisions from meeting, London, February 2013. URL: www.nets.nihr.ac.uk\/__data\/assets\/pdf_file\/0008\/66995\/outcomes-feb-2013.pdf (accessed 12 March 2014)."},{"key":"key20150715092047195_ref1-bib199","author":"","year":"2014","journal-title":"2013\/14 Winter Newsletter of the Centre for Health Economics and Medicines Evaluation (CHEME)"},{"key":"key20150715092047195_ref1-bib200","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/smll.201303433","article-title":"Topical delivery of avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes","volume":"10","author":"Davis","year":"2014","journal-title":"Small"},{"key":"key20150715092047195_ref1-bib201","unstructured":"National Institute for Health Research (NIHR). SR\u201313\/101\/47: Laser Photocoagulation for Non-Proliferative Diabetic Retinopathy; 2013. URL: www.nets.nihr.ac.uk\/projects\/sr\/1310147 (accessed 25 March 2014)."},{"key":"key20150715092047195_ref1-bib202","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0161-6420(13)38012-9","article-title":"Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETDRS report number 10","volume":"98","author":"","year":"1991","journal-title":"Ophthalmology"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta19510\/hta19510.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002251","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta19510\/hta19510.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:49:10Z","timestamp":1717980550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta19510\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":202,"journal-issue":{"issue":"51","published-online":{"date-parts":[[2015,7]]}},"alternative-id":["10.3310\/hta19510"],"URL":"https:\/\/doi.org\/10.3310\/hta19510","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}